Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | TSSK1B | Q9BXA7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7,8-Dihydrocalanolide B SCHEMBL29517130 | 1.00 | APAF1 (0.66) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| 7,8-Dihydrocalanolide B SCHEMBL15531956 | 1.00 | APAF1 (0.66) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| Costatolide SCHEMBL29397227 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| Costatolide SCHEMBL29402951 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| Costatolide SCHEMBL30544160 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| Calanolide A SCHEMBL140017 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| Costatolide SCHEMBL8927756 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| (-)-Calanolide A SCHEMBL8927754 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| (-)-Calanolide A SCHEMBL29803798 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 | |
| Calanolide A SCHEMBL30075237 | 0.79 | ALDH1A1 (1.00) | APAF1ALDH1A1MAPK1NPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | APAF1 375/4885ALDH1A1 1423/4885MAPK1 3065/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | APAF1 3397/4885ALDH1A1 1053/4885MAPK1 2479/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | APAF1 3165/4885ALDH1A1 72/4885MAPK1 4622/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | APAF1 375/4885ALDH1A1 1423/4885MAPK1 3065/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | APAF1 3397/4885ALDH1A1 1053/4885MAPK1 2479/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | APAF1 3165/4885ALDH1A1 72/4885MAPK1 4622/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | APAF1 900/4885ALDH1A1 590/4885MAPK1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.